GSGabrielle Schwartzman

Gabrielle Schwartzman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gabrielle Schwartzman has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Escalated Infliximab Dosing in Hidradenitis Suppurativa: A National Survey of Expert Practice

    by Adarsh Shidhaye, Nicole Edmonds, Gabrielle Schwartzman, Lindsey Buscemi, R. Hal Flowers

  • The Dermatologist's Role in Addressing the Resurgence of Measles in the United States and Globally

    by Gabrielle Schwartzman, Kenneth E. Greer, Barrett J. Zlotoff

  • Navigating patient portal overuse: Ethical strategies for compassionate care

    by Gabrielle Schwartzman, Aaron D. Smith, Pradip Ramamurti, R. Hal Flowers, Jane M. Grant-Kels

  • Open Access

    Cystic fibrosis dermatitis arthritis syndrome: A series of four cases

    by Gabrielle Schwartzman, Barrett J. Zlotoff, Alejandro A. Gru, Darren J. Guffey

    Dermatologic manifestations of cystic fibrosis (CF) include nutrient deficiency dermatoses, vasculitis, transient reactive papulotranslucent acrokeratodema, digital clubbing, and increased rates of atopy and drug reactions. Few cases of a characteristic eruption in patients with episodic arthritis of CF have been described with prior reports primarily occurring outside of the dermatology literature. We report four cases consistent with this presentation to add to the literature and propose a new and unifying name to recognize this entity as cystic fibrosis dermatitis arthritis syndrome (CF‐DAS). Clinical suspicion should remain high in young female patients with cystic fibrosis presenting with episodic joint pain and rash, independent of pulmonary exacerbations.

  • Cutaneous melioidosis: An updated review and primer for the dermatologist

    by Gabrielle Schwartzman, Soumya A. Reddy, Scott H. Berg, Bart J. Currie, Arturo P. Saavedra


  • Association of Adult Atopic Dermatitis Severity with Decreased Physical Activity: A Cross-sectional Study

    by Gabrielle Schwartzman, Donald Lei, Adnan Ahmed, Rajeev Chavda, Sylvie Gabriel, Jonathan I. Silverberg

    Background: Atopic dermatitis (AD) is associated with chronic pruritus, skin pain, sleep deprivation, depression, and anxiety, which may lead to decreased physical activity (PA). Objective: The aim of the study is to elucidate the impact of disease and itch severity on PA in adult AD. Methods: This is a prospective dermatology practice–based study of 955 AD patients (ages 18–97 years). Results: In multivariable logistic regression models controlling for age, sex, race/ethnicity, and asthma history, patient-reported global AD severity (PtGA), Patient-Oriented Eczema Measure, Eczema Area and Severity Index (EASI), and Investigator's Global Assessment (IGA) were associated with itch impairing light PA, moderate PA, and vigorous PA, as well as higher Patient-Reported Outcomes Measurement Information System Itch Questionnaire PA T -scores. Higher objective Scoring AD (O-SCORAD) was associated with itch impairing moderate PA. In bivariable analyses, performing greater than or equal to 30 minutes of light PA greater than or equal to 1 day a week was decreased with higher PtGA, Patient-Oriented Eczema Measure, and EASI; greater than or equal to 30 minutes of moderate PA greater than or equal to 1 day a week was decreased with PtGA, EASI, O-SCORAD, and IGA; and greater than equal to 30 minutes of vigorous PA was decreased with patient-reported AD severity, EASI, O-SCORAD, and IGA. In multivariable logistic regression models, the impact of itch on PA was inversely associated with light PA, moderate PA, and vigorous PA. Conclusion: Adult AD patients with more severe disease have decreased levels of PA secondary to itch.


  • Top Cited Papers

    Syphilis in Dermatology: Recognition and Management

    by Cleo Whiting, Gabrielle Schwartzman, Amor Khachemoune

    The incidence of syphilis has been increasing in the USA since 2000. Notably, the coronavirus disease 2019 pandemic negatively impacted the public health efforts to contain the spread of sexually transmitted diseases including syphilis and congenital syphilis. Clinical manifestations of syphilis are predominantly mucocutaneous lesions, thus dermatologists are primed to recognize the myriad presentations of this disease. Primary syphilis is classically characterized by a painless transient chancre most often located in the genital area. Secondary syphilis typically manifests clinically as systemic symptoms in addition to a mucocutaneous eruption of which a variety of forms exist. Although less common in the era of effective penicillin treatment, late clinical manifestations of syphilis are described as well. In addition to recognition of syphilis on physical examination, several diagnostic tools may be used to confirm infection. Treponema pallidum spirochetes may be detected directly using histopathologic staining, darkfield microscopy, direct fluorescent antibody, and polymerase chain reaction assays. A table detailing the histopathologic features of syphilis is included in this article. Serologic testing, non-treponemal and treponemal tests, is the preferred method for screening and diagnosing syphilis infections. Two serologic testing algorithms exist to aid clinicians in diagnosing positive syphilis infection. Determining the correct stage of syphilis infection combines results of serologic tests, patient history, and physical examination findings. Using the current Centers for Disease Control and Prevention case definitions and treatment guidelines, a management algorithm is proposed here. Penicillin remains the pharmacological treatment of choice although specific clinical situations allow for alternative therapies. Syphilis is a reportable disease in every state and should be reported by stage according to individual state requirements. Screening recommendations are largely based upon risks encountered through sexual exposures. Likewise, sexual partner management includes evaluating and treating persons exposed to someone diagnosed with an infective stage of syphilis. Close clinical follow-up and repeat testing are recommended to ensure appropriate response to treatment. This guide will discuss the current epidemiology of syphilis and focus on practice aspects of diagnosis and management, including public health reporting.


  • Open Access

    Managing Spiritual Care Departments During the COVID-19 Pandemic: A Qualitative Study

    by Beth L. Muehlhausen, Cate Michelle Desjardins, Christa Chappelle, Gabrielle Schwartzman, Beba Tata-Mbeng, George Fitchett

    This qualitative study reports how 20 spiritual care leaders provided leadership in the early months of the COVID-19 pandemic. The patterns and themes that emerged centered around the changing world of chaplaincy, the administrative role of the leader, and the personal story of the leader. Spiritual care leaders demonstrated creativity with the potential to shape chaplaincy in positive ways, expanding the reach of spiritual care.


  • Longitudinal course and phenotypes of health‐related quality of life in adults with atopic dermatitis

    by G. Schwartzman, D. Lei, A. Ahmed, R. Chavda, S. Gabriel, J. I. Silverberg

    Background The real-world course of health-related quality of life (HRQOL) in atopic dermatitis (AD) is not well established. Objective To examine predictors, longitudinal course, and phenotypes of HRQOL in adult AD patients. Methods A prospective dermatology-practice based study of 955 AD patients (age 18-97 years). Patients were assessed at baseline and approximately 6, 12, 18 and 24 months. Health-related quality of life was assessed using PROMIS Global Health (PGH) 10-item short-form. AD severity and impact was assessed by patient-reported global AD severity, Patient-Oriented Eczema Measure (POEM), Eczema Area and Severity Index (EASI), objective-SCORing AD (SCORAD), Investigator’s Global Assessment (IGA), Numerical Rating Scale (NRS) average and worst-itch, PROMIS sleep-related impairment, and Patient Health Questionnaire (PHQ)-9. Repeated-measures regression models were constructed to examine itch over time. Results In multivariable linear regression models controlling for age, race/ethnicity, history of asthma, hay fever, and food allergy, baseline PGH-physical T-scores were inversely associated with patient-reported global AD severity, POEM, EASI, objective-SCORAD, IGA, NRS average and worst-itch, PROMIS SRI, and PHQ-9, with stepwise decreases of physical health with worsening severity. PGH-mental T-scores were associated with all aforementioned severity measures aside from POEM. In multivariable repeated measures linear regression models, decreased PGH-mental and PGH-physical T-scores and mapped EQ-5D over time were associated with self-reported global AD severity, NRS worst and average-itch, POEM, PROMIS SD and SRI, EASI, objective-SCORAD, IGA, and PHQ-9 scores. Latent class analysis identified six classes of HRQOL, which were associated with measures of AD severity, non-white race, Hispanic ethnicity, and public insurance, but not age or sex. Conclusion AD patients have a heterogeneous longitudinal course and distinct patterns of HRQOL. Many patients had fluctuating HRQOL over time. Most patients with moderate-severe disease at baseline had persistent HRQOL impairment over time.